Eli Casdin

Insider Reports History

Reporting-owner location: New York, NY
Latest reporting-owner signature: /s/ Eli Casdin
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Eli Casdin

Form 4 holding Director, 10%+ Owner

GeneDx Holdings Corp.

Security class: Class A Common Stock
Shares / value: 3,507,164
Estimated value: $304,807,623
Report date: 18 Jun 2025
Price: $86.91
Ownership: See Casdin Partners Master Fund, LP

Form 4 holding Director, 10%+ Owner

STANDARD BIOTOOLS INC.

Security class: Common Stock
Shares / value: 72,100,000
Estimated value: $89,404,000
Report date: 26 Feb 2026
Price: $1.24
Ownership: Casdin Partners Master Fund, L.P.

Form 4 holding Director, 10%+ Owner

GeneDx Holdings Corp.

Security class: Class A Common Stock
Shares / value: 333,144
Estimated value: $28,953,545
Report date: 18 Jun 2025
Price: $86.91
Ownership: See CMLS Holdings LLC

Form 4 holding Director

Tenaya Therapeutics, Inc.

Security class: Common Stock
Shares / value: 6,078,860
Estimated value: $25,895,944
Report date: 17 Nov 2022
Price: $4.26
Ownership: Indirect

Form 4 holding Director, 10%+ Owner

STANDARD BIOTOOLS INC.

Security class: Common Stock
Shares / value: 13,939,637
Estimated value: $17,285,149
Report date: 26 Feb 2026
Price: $1.24
Ownership: Casdin Private Growth Equity Fund II, L.P.

Form 4 holding Director, 10%+ Owner

STANDARD BIOTOOLS INC.

Security class: Common Stock
Shares / value: 2,954,053
Estimated value: $3,456,242
Report date: 26 Feb 2026
Price: $1.17
Ownership: Direct

Form 4 holding Director, 10%+ Owner

STANDARD BIOTOOLS INC.

Security class: Common Stock
Shares / value: 2,744,219
Estimated value: $3,402,831
Report date: 26 Feb 2026
Price: $1.24
Ownership: By Casdin Private Growth Equity Fund, L.P.

Form 4 holding Director, 10%+ Owner

GeneDx Holdings Corp.

Security class: Class A Common Stock
Shares / value: 19,247
Estimated value: $1,672,756
Report date: 18 Jun 2025
Price: $86.91
Ownership: See Casdin Partners GP, LLC

Form 4 holding Director, 10%+ Owner

STANDARD BIOTOOLS INC.

Security class: Stock Option (Right to buy)
Shares / value: 125,660
Estimated value: $270,077
Report date: 20 Jun 2025
Price: $3.74
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Tenaya Therapeutics, Inc.

Security class: Warrant
Shares / value: 1,354,111
Estimated value
Report date: 17 Nov 2022
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Tenaya Therapeutics, Inc.

Security class: Stock Option (Right to buy)
Shares / value: 39,727
Estimated value
Report date: 10 Jun 2022
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Absci Corp

Security class: Stock Option (right to buy)
Shares / value: 28,700
Estimated value
Report date: 08 Jun 2022
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Century Therapeutics, Inc.

Security class: Stock Option (right to buy)
Shares / value: 19,872
Estimated value
Report date: 09 Jun 2022
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

EQRx, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value
Report date: 09 Nov 2023
Price: $2.21
Ownership: Indirect

Form 4 holding 10%+ Owner

EQRx, Inc.

Security class: Earn-out Shares
Shares / value: 0
Estimated value
Report date: 09 Nov 2023
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

EQRx, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 0
Estimated value
Report date: 09 Nov 2023
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

EQRx, Inc.

Security class: Warrants to purchase Class A Common Stock (right to buy)
Shares / value: 0
Estimated value
Report date: 09 Nov 2023
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, 10%+ Owner

GeneDx Holdings Corp.

Security class: Restricted Stock Unit
Shares / value: 0
Estimated value
Report date: 18 Jun 2025
Price
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Director, 10%+ Owner

SomaLogic, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value
Report date: 05 Jan 2024
Price: $2.43
Ownership: By Casdin Master Fund, L.P.

Form 4 holding Director, 10%+ Owner

SomaLogic, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value
Report date: 05 Jan 2024
Price: $2.43
Ownership: By Casdin Private Growth Equity Fund, L.P.

Form 4 holding Director, 10%+ Owner

SomaLogic, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value
Report date: 05 Jan 2024
Price: $2.43
Ownership: By CMLS Holdings II LLC

Form 4 holding Director, 10%+ Owner

SomaLogic, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value
Report date: 05 Jan 2024
Price: $2.43
Ownership: Direct

Form 4 holding Director, 10%+ Owner

SomaLogic, Inc.

Security class: Restricted Stock Unit
Shares / value: 0
Estimated value
Report date: 05 Jan 2024
Price: $2.43
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, 10%+ Owner

SomaLogic, Inc.

Security class: Stock Option (Right to buy)
Shares / value: 0
Estimated value
Report date: 05 Jan 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, 10%+ Owner

SomaLogic, Inc.

Security class: Warrant to purchase common stock (Right to buy)
Shares / value: 0
Estimated value
Report date: 05 Jan 2024
Price
Ownership: By CMLS Holdings II LLC
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Eli Casdin

4 LAB

STANDARD BIOTOOLS INC.

Report period: 26 Feb 2026
Transactions: 1
Transaction value: +$61,999
Accepted by SEC: 02 Mar 2026, 20:02
Role: Director, 10%+ Owner
Next action: Open filing details

4 LAB

STANDARD BIOTOOLS INC.

Report period: 20 Jun 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 24 Jun 2025, 18:57
Role: Director, 10%+ Owner
Next action: Open filing details

4/A WGS

GeneDx Holdings Corp.

Report period: 18 Jun 2025
Transactions: 3
Transaction value: $0
Accepted by SEC: 07 Aug 2025, 19:41
Role: Director, 10%+ Owner
Next action: Open filing details

4 LAB

STANDARD BIOTOOLS INC.

Report period: 19 Jul 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 23 Jul 2024, 18:05
Role: Director, 10%+ Owner
Next action: Open filing details

4 LAB

STANDARD BIOTOOLS INC.

Report period: 28 Jun 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 02 Jul 2024, 17:17
Role: Director, 10%+ Owner
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 26 Jun 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 27 Jun 2024, 16:14
Role: Director, 10%+ Owner
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 20 Jun 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 24 Jun 2024, 19:04
Role: Director, 10%+ Owner
Next action: Open filing details

4 LAB

STANDARD BIOTOOLS INC.

Report period: 20 Feb 2024
Transactions: 1
Transaction value: +$57,000
Accepted by SEC: 22 Feb 2024, 17:01
Role: Director, 10%+ Owner
Next action: Open filing details

SomaLogic, Inc.

Report period: 05 Jan 2024
Transactions: 10
Transaction value: $0
Accepted by SEC: 09 Jan 2024, 21:46
Role: Director, 10%+ Owner
Next action: Open filing details

4 LAB

STANDARD BIOTOOLS INC.

Report period: 05 Jan 2024
Transactions: 10
Transaction value: $0
Accepted by SEC: 09 Jan 2024, 18:06
Role: Director, 10%+ Owner
Next action: Open filing details

EQRx, Inc.

Report period: 09 Nov 2023
Transactions: 9
Transaction value: $0
Accepted by SEC: 14 Nov 2023, 08:33
Role: 10%+ Owner
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 21 Jul 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 25 Jul 2023, 16:14
Role: Director, 10%+ Owner
Next action: Open filing details

4 LAB

STANDARD BIOTOOLS INC.

Report period: 14 Jun 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 16 Jun 2023, 20:49
Role: Director
Next action: Open filing details

4 LAB

STANDARD BIOTOOLS INC.

Report period: 17 May 2023
Transactions: 3
Transaction value: +$2,631,335
Accepted by SEC: 19 May 2023, 21:02
Role: Director, 10%+ Owner
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 02 May 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 04 May 2023, 16:04
Role: Director
Next action: Open filing details

SomaLogic, Inc.

Report period: 17 Mar 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 22 Mar 2023, 06:02
Role: Director
Next action: Open filing details

4 WGS

GeneDx Holdings Corp.

Report period: 31 Jan 2023
Transactions: 2
Transaction value: +$30,000,000
Accepted by SEC: 02 Feb 2023, 15:05
Role: Director, 10%+ Owner
Next action: Open filing details

EQRx, Inc.

Report period: 01 Jan 2023
Transactions: 3
Transaction value: $0
Accepted by SEC: 04 Jan 2023, 20:55
Role: 10%+ Owner
Next action: Open filing details

4 TNYA

Tenaya Therapeutics, Inc.

Report period: 17 Nov 2022
Transactions: 2
Transaction value: +$9,998,644
Accepted by SEC: 25 Nov 2022, 18:05
Role: Director
Next action: Open filing details

EQRx, Inc.

Report period: 30 Sep 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 04 Oct 2022, 20:24
Role: Director, 10%+ Owner
Next action: Open filing details

SomaLogic, Inc.

Report period: 29 Sep 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 14 Dec 2022, 16:40
Role: Director
Next action: Open filing details

4 LAB

STANDARD BIOTOOLS INC.

Report period: 15 Jun 2022
Transactions: 2
Transaction value: +$79,182
Accepted by SEC: 17 Jun 2022, 18:04
Role: Director
Next action: Open filing details

4 TNYA

Tenaya Therapeutics, Inc.

Report period: 10 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 13 Jun 2022, 20:45
Role: Director
Next action: Open filing details

4 IPSC

Century Therapeutics, Inc.

Report period: 09 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 10 Jun 2022, 16:22
Role: Director
Next action: Open filing details

4 ABSI

Absci Corp

Report period: 08 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 10 Jun 2022, 16:51
Role: Director
Next action: Open filing details

4/A WGS

Sema4 Holdings Corp.

Report period: 02 May 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 May 2022, 18:56
Role: Director
Next action: Open filing details

4 WGS

Sema4 Holdings Corp.

Report period: 29 Apr 2022
Transactions: 1
Transaction value: +$45,750,000
Accepted by SEC: 03 May 2022, 16:01
Role: Director
Next action: Open filing details

4 WGS

Sema4 Holdings Corp.

Report period: 27 Apr 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 12 May 2022, 20:20
Role: Director
Next action: Open filing details

4 LAB

STANDARD BIOTOOLS INC.

Report period: 04 Apr 2022
Transactions: 3
Transaction value: $0
Accepted by SEC: 06 Apr 2022, 17:54
Role: Director, 10%+ Owner
Next action: Open filing details

3 LAB

STANDARD BIOTOOLS INC.

Report period: 04 Apr 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 06 Apr 2022, 17:53
Role: Director
Next action: Open filing details

SomaLogic, Inc.

Report period: 01 Mar 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 Mar 2022, 20:08
Role: Director
Next action: Open filing details

4/A

EQRx, Inc.

Report period: 17 Dec 2021
Transactions: 13
Transaction value: +$50,000,000
Accepted by SEC: 23 Dec 2021, 19:47
Role: Director, 10%+ Owner
Next action: Open filing details

SomaLogic, Inc.

Report period: 27 Oct 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 13 Dec 2021, 15:39
Role: Director
Next action: Open filing details

4 WGS

Sema4 Holdings Corp.

Report period: 15 Oct 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 19 Oct 2021, 19:19
Role: Director
Next action: Open filing details

SomaLogic, Inc.

Report period: 01 Sep 2021
Transactions: 5
Transaction value: +$25,000,000
Accepted by SEC: 03 Sep 2021, 20:08
Role: Director
Next action: Open filing details

4 TNYA

Tenaya Therapeutics, Inc.

Report period: 03 Aug 2021
Transactions: 6
Transaction value: +$12,750,000
Accepted by SEC: 04 Aug 2021, 18:32
Role: Director, 10%+ Owner
Next action: Open filing details

3 TNYA

Tenaya Therapeutics, Inc.

Report period: 29 Jul 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 29 Jul 2021, 19:31
Role: Director, 10%+ Owner
Next action: Open filing details

4 ABSI

Absci Corp

Report period: 26 Jul 2021
Transactions: 7
Transaction value: -$538,356
Accepted by SEC: 28 Jul 2021, 16:30
Role: Director
Next action: Open filing details

4 WGS

Sema4 Holdings Corp.

Report period: 22 Jul 2021
Transactions: 4
Transaction value: $0
Accepted by SEC: 27 Jul 2021, 06:09
Role: Director
Next action: Open filing details

3 ABSI

Absci Corp

Report period: 21 Jul 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 21 Jul 2021, 20:52
Role: Director, 10%+ Owner
Next action: Open filing details

4 IPSC

Century Therapeutics, Inc.

Report period: 22 Jun 2021
Transactions: 3
Transaction value: +$15,000,000
Accepted by SEC: 22 Jun 2021, 16:31
Role: Director
Next action: Open filing details

4 IPSC

Century Therapeutics, Inc.

Report period: 17 Jun 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 21 Jun 2021, 16:33
Role: Director
Next action: Open filing details

3 IPSC

Century Therapeutics, Inc.

Report period: 17 Jun 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 17 Jun 2021, 17:09
Role: Director
Next action: Open filing details

Insider Reports History

Continue from this owner filing history

Reported holdings for Eli Casdin

Insider Reports Filed by Eli Casdin